Skip to content
Search

Latest Stories

Over 5 million women ‘not up to date’ with cervical screening – NHS report reveals

NHS England is urging women to come forward for cervical screening
gettyimages

Cervical screening helps detect human papillomavirus (HPV), which causes over 99% of cervical cancers

NHS England is urging women to come forward for cervical screening as a new report reveals that over five million individuals are not up to date with their routine check-ups

The NHS Cervical Screening Programme, England 2023-2024 annual report, published today, shows that 68.8 per cent of women aged 25 to 64 were screened within the recommended timeframe, a slight increase from 68.7per cent the previous year. The screening rate was higher for those aged 50 to 64 at 74.3 per cent compared with 25 to 49-year-olds at 66.1per cent.


In 2023-2024, a total of 5.12 million women aged 25 to 64 in England were due for a test.

NHS England invited all of them to book an appointment, and 3.25 million were tested during the year, according to the report.

NHS has set an ambitious target of eliminating cervical cancer by 2040 by ensuring all eligible individuals have access to HPV vaccination and cervical screening.

Cervical screening plays a crucial role in preventing cervical cancer by detecting the human papillomavirus (HPV), which causes over 99 per cent of cervical cancers.

Sue Mann, NHS England’s national clinical director for women’s health, encourages anyone invited for screening to take action.

“If you have previously missed your appointment, do not hesitate to reach out to your GP practice or sexual health clinic to schedule a new one. Taking this proactive step could potentially save your life,” she said.

Sophia Lowes, senior health information manager at Cancer Research UK, emphasised the importance of cervical screening in saving thousands of lives each year.

Helen Hyndman MBE, nurse service co-ordinator for The Eve Appeal, reiterated the need for both HPV vaccination and cervical screening to help prevent cervical cancer.

The HPV vaccine can not only protect against cervical cancer by also other cancers including anal, mouth and throat, head and neck, and penile cancers caused by the HPV virus.

However, attending cervical screening appointments remains important even if you have been vaccinated against HPV, as the vaccine does not protect you from all types of HPV.

Cervical screening appointments can be booked through GP practices and some sexual health clinics also offer the service.

NHS England is also implementing new initiatives to make screening more accessible, such as allowing women to book appointments through the NHS App.

Earlier this month, the NHS announced plans to fully digitise screening, starting with a new "ping and book" service that will send alerts to phones to remind women they are due or overdue an appointment.

This service will first roll out for breast screening and expand to cervical screening in Spring 2025.

Future plans also include introducing HPV self-sample kits, which allow individuals to collect their samples for testing at home.

More For You

Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less